• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRCA1 和 BRCA2 基因突变携带者对侧乳腺癌的预测因素。

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

机构信息

Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada.

出版信息

Br J Cancer. 2011 Apr 26;104(9):1384-92. doi: 10.1038/bjc.2011.120. Epub 2011 Apr 12.

DOI:10.1038/bjc.2011.120
PMID:21487411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3101934/
Abstract

PURPOSE

The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk.

PATIENTS AND METHODS

Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up.

RESULTS

Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8%; P=0.003). Women aged <50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36%; P=0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95% CI 0.30-0.76; P=0.002).

CONCLUSION

The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.

摘要

目的

本研究旨在评估 BRCA1 和 BRCA2 携带者发生对侧乳腺癌的风险,并衡量宿主、家族史和癌症治疗相关因素对风险的影响程度。

方法

患者为 810 名患有 I 期或 II 期乳腺癌的女性,这些患者的家族中发现了 BRCA1 或 BRCA2 突变。患者从癌症首次诊断开始随访,直至对侧乳房切除术、对侧乳腺癌、死亡或最后一次随访。

结果

总体而言,149 例(18.4%)患者发生对侧乳腺癌。BRCA1 突变患者 15 年的对侧乳腺癌累积发生率为 36.1%,BRCA2 突变患者为 28.5%。诊断乳腺癌时年龄小于 50 岁的女性,与年龄大于 50 岁的女性相比,15 年内发生对侧乳腺癌的可能性明显更高(37.6% vs. 16.8%;P=0.003)。年龄<50 岁且有 2 个或更多有早发性乳腺癌的一级亲属的女性,发生对侧乳腺癌的风险较高,而一级亲属中有较少或没有乳腺癌的女性(50% vs. 36%;P=0.005)。卵巢切除术降低了对侧乳腺癌的风险(RR 0.47;95%CI 0.30-0.76;P=0.002)。

结论

BRCA 突变携带者对侧乳腺癌的风险随诊断年龄的增加而降低,随受影响一级亲属数量的增加而增加。卵巢切除术可降低携带 BRCA 突变的年轻女性对侧乳腺癌的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0536/3101934/a78539a199a1/bjc2011120f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0536/3101934/a78539a199a1/bjc2011120f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0536/3101934/a78539a199a1/bjc2011120f1.jpg

相似文献

1
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.BRCA1 和 BRCA2 基因突变携带者对侧乳腺癌的预测因素。
Br J Cancer. 2011 Apr 26;104(9):1384-92. doi: 10.1038/bjc.2011.120. Epub 2011 Apr 12.
2
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.携带BRCA1和BRCA2基因突变者的对侧乳腺癌
J Clin Oncol. 2004 Jun 15;22(12):2328-35. doi: 10.1200/JCO.2004.04.033.
3
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者的乳腺癌、卵巢癌和对侧乳腺癌风险。
JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.
4
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.对来自携带BRCA1或BRCA2基因突变家族的乳腺癌或卵巢癌女性使用基因检测、预防性乳房切除术和卵巢切除术。
J Clin Oncol. 2003 May 1;21(9):1675-81. doi: 10.1200/JCO.2003.09.052.
5
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.他莫昔芬与BRCA1和BRCA2突变携带者对侧乳腺癌风险:一项病例对照研究。遗传性乳腺癌临床研究组。
Lancet. 2000 Dec 2;356(9245):1876-81. doi: 10.1016/s0140-6736(00)03258-x.
6
Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).BRCA1 和 BRCA2 基因突变携带者及其他高危女性的对侧预防性乳房切除术——凯思琳·坎宁安家族乳腺癌研究联合会(kConFab)的研究
Breast Cancer Res Treat. 2010 Apr;120(3):715-23. doi: 10.1007/s10549-009-0497-8. Epub 2009 Aug 11.
7
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.他莫昔芬与携带BRCA1和BRCA2基因者的对侧乳腺癌:最新进展
Int J Cancer. 2006 May 1;118(9):2281-4. doi: 10.1002/ijc.21536.
8
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.BRCA1 和 BRCA2 基因突变携带者的卵巢切除术与对侧乳腺癌风险。
Breast Cancer Res Treat. 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.
9
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.携带BRCA1和BRCA2基因突变者的对侧乳腺癌风险。
J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.
10
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.BRCA1和BRCA2突变携带者的双侧卵巢切除术与乳腺癌风险
J Natl Cancer Inst. 2016 Sep 6;109(1). doi: 10.1093/jnci/djw177. Print 2017 Jan.

引用本文的文献

1
Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours.中国恶性黑色素瘤合并其他原发性肿瘤患者的临床特征、预后及基因突变差异。
Ann Med. 2025 Dec;57(1):2493769. doi: 10.1080/07853890.2025.2493769. Epub 2025 May 3.
2
Successful BRCA2 Mutation Detection via Tissue-Based Gene Panel Testing in Post-bone Marrow Transplant Breast Cancer: Implications for Precision Medicine.通过基于组织的基因检测panel检测骨髓移植后乳腺癌中BRCA2突变的成功案例:对精准医学的启示
Cureus. 2025 Feb 8;17(2):e78729. doi: 10.7759/cureus.78729. eCollection 2025 Feb.
3

本文引用的文献

1
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.BRCA1 或 BRCA2 基因突变女性的癌症家族史和癌症风险。
J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8. doi: 10.1093/jnci/djq443. Epub 2010 Nov 23.
2
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.基于人群的研究:BRCA1 或 BRCA2 基因突变携带者发生对侧原发性乳腺癌的风险。
J Clin Oncol. 2010 May 10;28(14):2404-10. doi: 10.1200/JCO.2009.24.2495. Epub 2010 Apr 5.
3
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Recurrence Patterns and Long-Term Results After Curative Surgery for Patients With Breast Cancer.
乳腺癌患者根治性手术后的复发模式及长期结果
Ann Surg Oncol. 2025 Apr;32(4):2554-2568. doi: 10.1245/s10434-024-16726-3. Epub 2024 Dec 30.
4
Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis.BRCA1/2基因变异携带者对侧乳腺癌的二级风险降低策略:一项系统评价和荟萃分析
Adv Ther. 2025 Jan;42(1):106-131. doi: 10.1007/s12325-024-03054-x. Epub 2024 Nov 29.
5
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.癌症易感基因中的致病变异易导致乳腺导管原位癌。
Clin Cancer Res. 2025 Jan 6;31(1):130-138. doi: 10.1158/1078-0432.CCR-24-1884.
6
Synchronous Primary Gallbladder and Colon Adenocarcinoma: A Case Report and Systematic Literature Review.同步性原发性胆囊和结肠腺癌:一例报告及系统文献综述
Cureus. 2024 Sep 10;16(9):e69092. doi: 10.7759/cureus.69092. eCollection 2024 Sep.
7
Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies.辅助内分泌治疗与对侧乳腺癌风险:观察性研究的系统评价和荟萃分析
Cancer Causes Control. 2025 Feb;36(2):107-126. doi: 10.1007/s10552-024-01900-5. Epub 2024 Oct 9.
8
Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.BRCA1/2 野生型、高风险韩国乳腺癌患者对侧乳腺癌风险增加:一项回顾性队列研究。
Breast Cancer Res. 2024 Jan 22;26(1):14. doi: 10.1186/s13058-024-01769-x.
9
Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection.预防性输卵管卵巢切除术与 BRCA1/2 乳腺癌切除术后的生存
JAMA Surg. 2023 Dec 1;158(12):1275-1284. doi: 10.1001/jamasurg.2023.4770.
10
Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?携带BRCA基因突变者接受放射治疗后的对侧乳腺癌风险:我们该如何告知患者?
J Natl Cancer Inst. 2023 Nov 8;115(11):1243-1245. doi: 10.1093/jnci/djad129.
基于人群的研究中,BRCA1/BRCA2 突变携带者乳腺癌的辅助全身治疗与对侧乳腺癌风险。
Breast Cancer Res Treat. 2010 Sep;123(2):491-8. doi: 10.1007/s10549-010-0769-3. Epub 2010 Feb 5.
4
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.携带BRCA1和BRCA2基因突变者的对侧乳腺癌风险。
J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.
5
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.对BRCA1或BRCA2基因突变携带者行降低风险的输卵管卵巢切除术相关风险降低估计值的荟萃分析。
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.
6
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.国际BRCA1/2携带者队列研究中的初潮和绝经年龄与乳腺癌风险
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):740-6. doi: 10.1158/1055-9965.EPI-06-0829.
7
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.与散发性乳腺癌病例相比,BRCA2、BRCA1和非BRCA1/2家族遗传性乳腺癌的肿瘤特征、生存率及预后因素。
Eur J Cancer. 2007 Mar;43(5):867-76. doi: 10.1016/j.ejca.2006.12.009. Epub 2007 Feb 20.
8
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.他莫昔芬与携带BRCA1和BRCA2基因者的对侧乳腺癌:最新进展
Int J Cancer. 2006 May 1;118(9):2281-4. doi: 10.1002/ijc.21536.
9
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.BRCA1和BRCA2突变携带者双侧卵巢切除术后的乳腺癌风险:一项国际病例对照研究。
J Clin Oncol. 2005 Oct 20;23(30):7491-6. doi: 10.1200/JCO.2004.00.7138.
10
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.携带BRCA1和BRCA2基因突变者的对侧乳腺癌
J Clin Oncol. 2004 Jun 15;22(12):2328-35. doi: 10.1200/JCO.2004.04.033.